The Wnt/β-catenin pathway has been implicated in a subset of HCC where activating mutations in the β-catenin gene (CTNNB1) have been reported in 20%–40% of patients [7], [8]. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.